Immunovant

IMVT Mid Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$24.50

-2.39% today

52W: $12.72 – $29.25

52W Low: $12.72 Position: 71.3% 52W High: $29.25

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

—

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$5B

Market Capitalization

Revenue Growth

—

YoY Revenue Growth

Profit Margin

—

Net profit margin

ROE

-69.35%

Return on Equity

Beta

0.67

Market sensitivity

Short Interest

18.61%

% of float sold short

Avg. Volume

1,381,170

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

17 analysts

Avg. Price Target

$40.59

+65.67% upside

Target Range

$22.00 – $66.00

About the Company

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 362 Exchange: NMS